To better monitor, manage,
and understand every obesity.

Obesity care pathways face unprecedented clinical demand with the arrival of anti-obesity medications (AOMs). Healthcare teams must manage surging patient volumes while handling prolonged delays and operational pressures. Because pharmacology alone is not enough, prescribing therapy requires structured guidance between visits: managing side effects, addressing foundational questions, and delivering comprehensive biopsychosocial care. Boli was built to support your clinical practice.

+ 1 year

average wait time for specialized obesity consultations across many healthcare systems.Specialized Obesity Care Pathways

~50%

of symptomatic adverse events experienced by patients go unreported without structured PRO collection.Basch E. et al., JCO 2009 · Di Maio M. et al., JCO 2015

~65%

of adults initiating GLP-1 therapy for obesity discontinue within the first 12 months.Rodriguez PJ. et al., JAMA Netw Open, 2025 (PMID 39888616)

Millions

of patients eligible for covered medical obesity management.Health Technology Assessment Guidelines